- Home
- / Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals
Stock Price
£0
2024-10-29
Market Capitalization
£17.8 M
2024-10-29
Hemogenyx Pharmaceuticals Summary
Company Summary
- Overview
- Hemogenyx Pharmaceuticals, formerly Silver Falcon, is a pre-clinical stage biopharmaceutical company. It is engaged in bone marrow transplantation. The Company develops medicines and treatments to handle blood diseases.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- London, GB | view all locations
- Website
- http://silverfalconplc.com/
- Cybersecurity rating
Table of Contents
Hemogenyx Pharmaceuticals Financials
Summary Financials
- Net income (H1, 2024)
- (£2.8M)
- Cash (H1, 2024)
- £1.6M
- EBIT (H1, 2024)
- (£2.7M)
- Enterprise value
- $18.9M
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2025